Abstract
The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.
Original language | English |
---|---|
Number of pages | 158 |
Journal | Health technology assessment |
Volume | 9 |
Issue number | 15 |
Publication status | Published - May 2005 |
Keywords
- ADD-ON THERAPY
- QUALITY-OF-LIFE
- REFRACTORY PARTIAL EPILEPSY
- NEWLY-DIAGNOSED EPILEPSY
- COMPLEX PARTIAL SEIZURES
- PLACEBO-CONTROLLED TRIAL
- PARTIAL-ONSET SEIZURES
- RESISTANT PARTIAL EPILEPSY
- GAMMA-VINYL-GABA
- VISUAL-FIELD DEFECTS